Effect of an Albumin Infusion Treatment Protocol on Delayed Cerebral Ischemia and Relevant Outcomes in Patients with Subarachnoid Hemorrhage

• Published in: Neurocritical care 2023-08, Vol.39 (1), p.180-190
• Main Authors: Gempeler, Andrés, Gaviria, Leidy, Ortiz, Alejandra, Jaramillo, Natalia, Beltrán, Luis, Escobar, Sara, Rondón, Martín, Rosselli, Diego, Martinez-Buitrago, Jorge E., Mejía-Mantilla, Jorge H.
• Format: Article
• Language: English
• Subjects: Aneurysms; Blood pressure; Critical Care Medicine; Hemodynamics; Hemorrhage; Intensive; Intensive care; Internal Medicine; Ischemia; Medical imaging; Medicine; Medicine & Public Health; Neurology; Neurosurgery; Original Work; Physiology; Prevention; Pulmonary arteries; Review boards; Standard of care
• ISSN: 1541-6933; 1556-0961
• DOI: 10.1007/s12028-023-01731-3

Background An institutional management protocol for patients with subarachnoid hemorrhage (SAH) based on initial cardiac assessment, permissiveness of negative fluid balances, and use of a continuous albumin infusion as the main fluid therapy for the first 5 days of the intensive care unit (ICU) stay was implemented at our hospital in 2014. It aimed at achieving and maintaining euvolemia and hemodynamic stability to prevent ischemic events and complications in the ICU by reducing periods of hypovolemia or hemodynamic instability. This study aimed at assessing the effect of the implemented management protocol on the incidence of delayed cerebral ischemia (DCI), mortality, and other relevant outcomes in patients with SAH during ICU stay. Methods We conducted a quasi-experimental study with historical controls based on electronic medical records of adults with SAH admitted to the ICU at a tertiary care university hospital in Cali, Colombia. The patients treated between 2011 and 2014 were the control group, and those treated between 2014 and 2018 were the intervention group. We collected baseline clinical characteristics, cointerventions, occurrence of DCI, vital status after 6 months, neurological status after 6 months, hydroelectrolytic imbalances, and other SAH complication. Multivariable and sensitivity analyses that controlled for confounding and considered the presence of competing risks were used to adequately estimate the effects of the management protocol. The study was approved by our institutional ethics review board before study start. Results One hundred eighty-nine patients were included for analysis. The management protocol was associated with a reduced incidence of DCI (hazard ratio 0.52 [95% confidence interval 0.33–0.83] from multivariable subdistribution hazards model) and hyponatremia (relative risk 0.55 [95% confidence interval 0.37–0.80]). The management protocol was not associated with higher hospital or long-term mortality, nor with a higher occurrence of other unfavorable outcomes (pulmonary edema, rebleeding, hydrocephalus, hypernatremia, pneumonia). The intervention group also had lower daily and cumulative administered fluids compared with historic controls ( p